Introduction
Despite much work, the molecular pathogenesis of B cell chronic lymphocytic leukemia (CLL) remains obscure. The classical cytogenetic-lead approach to the molecular dissection of malignancy has thus far failed to allow the identification of the major 'players'. The reasons for this reflect not only the difficulties in obtaining metaphases from patients with CLL, but also the lack of a consistent and a genetically amenable lesion. Cytogenetic analysis of CLL supplemented with comparative genomic hybridization and interphase FISH studies, have shown recurrent deletions involving regions such as 6q21, 11q22-q23, 13q14.3 and 17p13.1. 1 According to the Knudson hypothesis, such deletions may mark the presence of tumor suppressor genes (TSGs) with deletion of one allele and mutation of the other. Whilst this hypothesis has worked well in the isolation of inherited cancer genes, the number of somatically mutated TSGs remains small. There are a variety of possible reasons for this. 2 Firstly, somatically acquired deletions are frequently large, spanning several megabases of DNA and may be secondary events, present only in a fraction of malignant cells. Even with the completion of the first draft of the human genome, identification of the key gene within the involved region (such as the commonly deleted region of 13q14 in CLL) may therefore be extremely difficult. [3] [4] [5] Alternatively, for some genes, loss of one copy without mutation of the remaining allele (haploinsufficiency) may be sufficient, whilst for other TSGs, epigenetic factors, such as promoter methylation may also contribute to loss of expression. 6, 7 Furthermore, in CLL, some 13q14 deletions may in fact be associated with chromosomal translocations, suggesting that some of these events are complex and may be associated with loss of expression of some genes, but possibly over-expression of others. 8 Given these difficulties, an alternative approach has been to search for abnormalities within genes of importance in the pathogenesis of other subtypes of B cell malignancy. The B cell non-Hodgkin's lymphomas (B-NHL) are in many instances, characterized by specific and recurrent chromosomal translocations involving the immunoglobulin (IG) loci. [9] [10] [11] Molecular cloning of such translocations has allowed, and continues to allow, cloning of genes intimately involved in the development of both normal and malignant B cells. [12] [13] [14] [15] These genes may be involved in the pathogenesis of B cell malignancies, not only through chromosomal translocation, but also through their direct involvement in genomic amplifications and through changes in methylation. Moreover, molecular analysis of the breakpoint sequences allows identification of the mechanisms and timing of chromosomal translocations in B cell development. 10, 16 Here, we review data concerning the configuration of the IG genes in CLL and how studies of these genes have shed light on the pathogenesis and progression of CLL.
Somatic recombination and hypermutation of the IG genes in normal B cells
The origins of antibody diversity reflect the actions of three fascinating genetic mechanisms summarized with reference to the immunoglobulin heavy chain (IGH) locus at the very telomere of the long arm of chromosome 14 at chromosome 14q32.33 in Figure 1 and reviewed in Refs 10 and 17 and Refs therein.
Firstly, somatic recombination of the dispersed IG gene segments is required to produce a functional IG gene. This was first demonstrated by Susumu Tonegawa, for which he won the Nobel prize for Medicine in 1987. 18 During the early stages of B cell differentiation within the bone marrow, diversity (D) and then variable (V) region gene segments undergo DNA sequence specific recombination with the joining (J) region segments in order to produce a contiguous VDJ gene. This is mediated by a complex of enzymes, including RAG1 and RAG2, which bind to and cleave specific DNA sequences. Part of the genetic diversity arises through the different junctions arising from the assortment of the various V, D and J segments. Cell surface expression of functional antibody molecules is necessary for the continued survival of early pre-B cells. Failure to undergo recombination successfully due to out-of-frame recombination, results in cell death by apoptosis. The dependence of B cell survival on maintained surface Ig expression persists until differentiation to memory B cells.
Figure 1
Schema showing the various configurations of the immunoglobulin heavy chain (IGH) locus on chromosome 14 during B cell differentiation. The IGH locus is located at the very telomere of the long arm of chromosome 14. It comprises 52 dispersed variable (V H ), 27 diversity (D H ) and six joining region (J H ) segments. VDJ H recombination occurs within the bone marrow and results in the formation of a contiguous gene segment. SHM and CSR occur in the germinal center within the lymph node via a related mechanism. Both involve doublestranded DNA breaks. Switch regions are shown in gold, constant regions in dark blue and enhancer regions in purple. Enhancer regions are located in the J H -C intron and 3′ of both C␣1 and C␣2; recently an additional enhancer region has been identified between C␦ and C␥3. Transcriptional orientation is shown by horizontal arrows.
of the V H promoter to a transcriptional enhancer located within the intron between the J H segments and C, immediately upstream of the repetitive S region. The anatomy of this enhancer, in terms of definition of protein binding sites, has been extensively studied. Apart from its profound effects in directing B cell-specific transcription, this small region of DNA has a number of other interesting properties. It also appears to act as an attachment site to the nuclear matrix and is, as well, an origin of DNA replication. [20] [21] [22] The intronic enhancer of both IG heavy and light chains is necessary for somatic hypermutation to occur. 23 Properties of the enhancer may also account for the differential subnuclear localization of the two IGH alleles observed in normal B cells and may account in part for the allelic exclusion of immunoglobulin proteins. 24 Interestingly, another IG enhancer or possibly an IGH locus control region (LCR) has been recently identified in a highly unstable region of genomic DNA between the C␦ and the first downstream C␥ gene, C␥3. This appears to function in the control of early B cell development although its role in mature B cell malignancies has not been investigated. 25 This region may also contain a number of nuclear matrix attachment regions. Breaks in this region are seen in at least 10% of cases of B cell precursor ALL, but comparable abnormalities in CLL have not been detected. 26 Secondly, somatic hypermutation (SHM) is necessary to produce antibodies with high affinity for antigen. This occurs primarily, but not exclusively, at the complementarity determining regions (CDRs), the antigen-binding sites of the V H genes. This process occurs within the germinal center following encounter with antigen. Cells expressing high-affinity antibody molecules are positively selected and differentiate into either memory B cells or plasma cells. Once selected, memory B cells no longer require surface immunoglobulin or antigen for continued long-term survival. 27 The signals that trigger SHM, the mechanism responsible and the reasons why some regions are hot spots for SHM are incompletely understood. 28, 29 In normal B cells, replacement mutations are clustered within the CDRs that encode the antibody-combining site, rather than the intervening framework regions (FR), which are responsible for the structural integrity of the variable region. The ratio of replacement mutations (R) resulting in a change in amino-acid content to silent mutations (S), which do not affect the protein structure, is therefore higher in CDR than in FW regions. The consequence of SHM is the selection of B cells that produce high affinity antibodies. Mutated cells that produce low affinity antibody or fail to produce antibody, like the equivalent B cell precursors in the bone marrow, undergo apoptosis within the germinal center. The finding of intraclonal heterogeneity in normal germinal centre B cells indicates that these cells may undergo more than one cycle of SHM.
Finally, shortly after SHM occurs within the germinal center, 30 the third recombination process, involving transposition of the completed VDJ gene to downstream constant (C H ) region segments is initiated resulting in antibody molecules with different effector functions. This is known as class switch recombination (CSR). CSR occurs between highly repetitive switch regions, which lie upstream of each of the IG constant region genes with the exception of C␦. However, despite the highly repetitive nature of individual switch regions, CSR does not represent homologous recombination. The discovery that an enzyme with homology to RNA editing enzymes human activation-induced cytidine deaminase (AID) is involved in both SHM and CSR indicates some common pathways in both processes. 31 All three recombination processes, including SHM, involve the introduction of double-stranded DNA breaks. 32, 33 It has thus been suggested that errors in all three processes may contribute to the pathogenesis of B cell malignancies in various
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ways, but principally through the generation of chromosomal translocations. 10, 32 A final point of interest concerning the immunoglobulin genes is that mature B cells express only one allele, a process known as allelic exclusion. In some instances, only one allele may be functional due to incorrect VDJ rearrangement resulting in an out-of-frame join. In others though, it is clear that both alleles are potentially functional. Nevertheless in all normal cells, and in the majority of neoplastic B cells it seems that only one allele is expressed. In a subgroup of CLL, it has been shown that this process is subverted with the simultaneous expression of two IGH alleles. 34, 35 This appears to occur quite frequently, in 8/122 (6%) of cases in one series. The possible biological and clinical significance of this observation is not known. Interestingly, allelic exclusion is also subverted in all cases with IG translocations since both the functional IG allele and the translocated oncogene at the other IG allele are expressed simultaneously. Allelic exclusion may result from the differential methylation of the IGH loci, and this may account for the differential nuclear sublocalization of the two alleles. 24, 36 In health, 60% of circulating B cells in the peripheral blood are naïve pre-germinal center cells which express surface IgM and IgD but not CD27, and have unmutated V H genes; 25% of these are CD5
+ . The remaining cells are post germinal center memory cells, which have undergone SHM and which express CD27. Approximately 40% are class switched, while the remainder express surface IgM and/or IgD, but not CD5.
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Analysis of the IG genes in B-CLL
V H mutations in CLL
V H gene analysis is increasingly being employed in the investigation of chronic B cell malignancies. 38 These may be classified as pre-germinal center, germinal center or post germinal center tumors depending on whether SM has occurred and if so whether there is intraclonal heterogeneity. However unexpected heterogeneity in V H gene status is being encountered in several B cell lymphomas that appear histologically uniform. 39 Technically, V H gene analysis may be performed on genomic DNA or cDNA. The advantage of using cDNA is that only the functional gene product is sequenced. If genomic DNA is used, the non-functional rearrangement is often detectable and also undergoes SHM in cells which have traversed the germinal center. PCR primers are usually selected such that the whole of the V H , D H and J H gene segments are amplified. Mutations are counted within the V H gene from the beginning of framework 1 to the end of framework 3. The presence of N additions between the V H and D H segments and the D H and J H segments precludes mutations within the CDR3 region from being counted. If a primer within the framework 1 region is used rather than in the V H gene leader sequence, the number of nucleotides that can be assessed for the presence of mutations is reduced and as mutations are rarely found within framework 1 the percentage of V H mutations may appear slightly higher. Assignment of a nucleotide change as a mutation rather than a polymorphism depends on a comparison of the tumor sequence with the normal germline sequence. Various databases are available to enable this comparison, but these differ in the number of polymorphic sites that are recognized. A further problem is that the incidence of polymorphisms differs among the V H gene families and Leukemia between different V H gene segments. Although Ͻ98% homology to the nearest germline sequence is regarded as evidence of SHM, this figure can only be an approximation until all the polymorphisms in every V H gene segment are known.
Initially V H gene sequencing was performed on gel-purified PCR products, which were then cloned into bacterial vectors. Sequencing a large number of clones from a single patient enables the incidence of intra-clonal heterogeneity to be determined. In CLL, this occurs only rarely and it is now more usual to sequence PCR products directly. However, it is possible that very small intraclonal variations may be missed using direct sequencing. Most sequence data have been derived from analysis of V H genes only. Damle et al 40 have also sequenced V L genes and found that in 5% of CLL cases mutations are restricted to the V L genes.
Early studies on small numbers of cases showed that V H genes were unmutated in CLL. 41 This was consistent with the hypothesis that CLL, together with mantle cell lymphoma, was derived from a subset of CD5 positive naive B cells. In 1994, Schroeder and Dighiero 42 reviewed the literature on V H gene status in CLL and noted that 36 of 75 cases had Ͻ98% homology to the nearest germline sequence. The presence of mutations in 40-70% of patients with CLL has subsequently been confirmed in a number of series that have investigated over 700 patients in total ( Table 1 ). The variation in the incidence of cases with SHM largely reflects the clinical stage of patients analyzed. In the Bournemouth series, 49% of Binet stage A patients and 69% of stage B or C patients had unmutated V H genes. 43 This difference is the probable explanation for the initial finding of unmutated V H genes in CLL since the cases selected for study were likely to have had advanced disease, emphasizing the dangers of extrapolating data on small numbers of cases to a whole disease.
CD38: a surrogate marker for V H mutational status
CD38 is a trans-membrane glycoprotein which is widely expressed on hemopoietic cells, but is expressed at high levels on germinal center B cells and plasma cells. CD38 is a novel enzyme capable of catalysing multiple reactions, including NAD glycohydrolase, ADP-ribosyl cyclase, cyclic ADP ribose hydrolase and base-exchange activities. The functions of the molecule are complex and multiple, but germinal center B cells are rescued from apoptosis by CD38-mediated signaling. The pathway used is the same as that used for B cell receptor for antigen/Ig signaling (reviewed in Ref. 44).
Damle et al 40 observed that Ͼ30% expression of CD38 on CD5
+ CLL cells was strongly associated with unmuat- 
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Leukemia ted V H genes, whereas all cases with mutated V H genes had Ͻ30% CD38 expression. Subsequent studies have confirmed the association between unmutated V H genes and high CD38 expression but discordant results (CD38-positive in mutated cases or CD38-negative in unmutated cases) have been found in 28-43% of patients. 45, 46 In addition, CD38 expression may vary in the course of the disease. In a sequential study of 41 patients, 10 showed changes in CD38 expression. 46 In the majority of these, a rise in CD38 expression followed chemotherapy suggesting that CD38-positive cells may be more resistant to treatment. CD38 expression alone cannot therefore be used as a surrogate marker for V H gene status.
Whether other cell surface proteins or combinations of proteins, indicative of B cell passage through the germinal center can be used to enhance the specificity and sensitivity of a FACs-based assay remains to be determined.
Prognostic significance of V H mutations in CLL
In 1999, Hamblin et al 40 and Damle et al 43 simultaneously reported the prognostic significance of V H gene status in CLL. Both groups used homology of у98% to the germ line sequence to define the absence of SHM. The median survival of unmutated cases was 117 and 108 months, respectively. In our series the median survival of mutated cases was 293 months, while the median survival in Damle's series had not been reached. These data have been corroborated in more recent studies. The median survival of unmutated cases was 77 months in a study that included 300 patients 47 and 108 months in a second study of 24 cases. 48 In neither study was the median survival of mutated cases reached. Maloum et al 49 noted that eight of 12 patients with unmutated V H genes died from CLL-related causes compared to only two of 27 cases with mutated V H genes.
The prognostic significance of V H gene status is evident within all clinical stages of CLL. In our own study the median survival of stage A patients with unmutated V H genes was 95 months compared to 293 months for patients with mutated V H genes. Although the prognostic significance of V H gene status is unequivocal, the relative importance of V H gene status in relation to other known prognostic factors is still uncertain. Some studies have found CD38 expression to be a weak independent prognostic factor in patients of known V H gene status, whereas others have not confirmed this finding. 45, 48, 50, 51 The prognostic significance of cytogenetic abnormalities in CLL is well documented. 1 Cases with a normal karyotype or deletion of chromosome 13q14 have a significantly better prognosis than cases with deletions of chromosomes 11q or 17p. Preliminary data from our own group 52 and from Krober et al 47 have shown that deletions of 11q and 17p are more common, but not exclusive to, cases with unmutated V H genes and that del 17p is an independent adverse prognostic factor in a multivariate analysis which includes clinical stage, V H gene status and CD38 expression. Pettitt et al 53 have recently shown that failure of CLL cells to upregulate expression of p21 in response to in vitro irradiation indicates p53 dysfunction due either to p53 mutation or inactivation of ATM. The same group has subsequently found that in vitro resistance to purine analogues is confined to a subgroup of patients with Ͻ5% divergence from the germline sequence and evidence of p53 dysfunction. 54 Whether the degree of SHM has prognostic significance remains controversial. If this was confirmed in larger series using a standardized method for assessing the percentage of V H gene mutations, then it would be difficult to reconcile these data with the concept that one subset of CLL has a better prognosis primarily because it is a disease of a post germinal center B cell. No studies have yet shown the prognostic value of V H gene status in patients in whom serum markers such as ␤-2 microglobulin or soluble CD23 have been measured.
Biased V H gene usage in CLL
The germline repertoire comprises 52 V H gene segments subdivided into seven families, six J H and 27 D H segments. 55 Some of these VDJ H segments are utilized more frequently than others in the normal B cell repertoire. There is increasing evidence that usage of the different gene segments is not random. 56 This biased usage occurs in part before antigen exposure since it is seen in the non-productive rearrangement, 57 but in part, is also due to antigen selection. A prime example of this in disease is the exclusive use of the V4-34 gene in monoclonal cold agglutinins directed against the Ii antigens.
Difficulties in identifying biased usage include incomplete knowledge of the normal repertoire and the influence of ageing, since there are data to suggest that the V H gene repertoire alters with advancing age. 58, 59 Total knowledge of the normal repertoire is currently based on an analysis of B cell clones from small numbers of healthy individuals. Nevertheless, many studies have noted that certain V H gene segments such as V1-69, V3-23 and V4-34 are regularly used in CLL. 41, 42, 60 Widhopf and Kipps 61 found that leukemic B cells which utilized 51p1, an allele of V1-69, also showed biased usage of D H and J H segments resulting in a long 'conserved' CDR3 region. Of particular interest is the distribution of mutations within the commonly used V H genes. Most V1-69 genes remain unmutated, whereas the converse is true for the V4-34 gene. The possible significance of this is discussed below.
The possible role of antigen selection in CLL
A number of studies have shown that the pattern of V H mutations is consistent with antigen selection in a minority of cases. 43, 48, 60 Interpretation of these data is problematic for a number of reasons. 60 Most studies have used the algorithm proposed by Chang and Casali 62 to define antigen selection, but recently Lossos et al 63 have suggested a different multinomial distribution model to assess antigen selection. When both models were applied to 86 cases, opposite conclusions about antigen selection were found in eight cases. Another potential problem is that if a transforming event that reduces susceptibility to apoptosis has occurred in leukemic cells prior to exposure to the mutator mechanism, then the selective pressure of antigen would no longer apply. Finally, until one or more antigens are discovered against which the leukemic clone is directed, then discussions on the incidence and importance of antigen selection in CLL remain hypothetical.
The biological significance of V H mutations
The clinical, morphological and genetic heterogeneity that exists within CLL is consistent with a slowly progressive neoplastic disorder characterized by genomic instability and in which patients may present at different stages of the disease. However, the discovery of two mutational subsets in CLL SPOTLIGHT raises the issue as to whether CLL is really two diseases rather than one. The only reasonable explanation for CLL cases with SHM, but without clonal heterogeneity, is that the final transforming event has occurred in a cell that has been exposed to the mutator mechanism, presumably within a germinal center. Unmutated cases, by analogy, are those that have not been exposed to the mutation process, although it is at least theoretically possible that cells could traverse a germinal center without undergoing hypermutation or that the neoplastic process could prevent cells from undergoing SHM.
More contentious is the nature of the unmutated cell. The phenotype of weak surface immunoglobulin and expression of CD23, CD27 and CD38 is not that of a naïve B cell, but more consistent with a cell which has been exposed to antigen and perhaps rendered anergic. The failure of such cells to undergo apoptosis may be a consequence of the neoplastic process, which promotes cell survival. The most compelling evidence that antigenic exposure has occurred is the finding of biased V H gene usage in cells that are unmutated. It is possible that a putative autoantigen or exogenous infective agent may be T independent or may bind antibody via the framework region (superantigen). In either case, B cell proliferation would not require entry in a germinal center. However, it should be stressed that there is no experimental evidence to support these hypotheses.
Preliminary data from cDNA microarray experiments suggest that all CLL cells have a common expression signature, but in addition there are differences between the two subsets defined by V H mutations. 64, 65 In particular there is up-regulation of genes responsible for signaling through the B cell receptor in cases with unmutated V H genes. Studies investigating the genetic, biochemical and functional differences between the two subsets are ongoing, but it is already clear that V H gene mutational status is a powerful prognostic factor in CLL, which should enable new therapies to be targeted to patients with aggressive disease and avoid over-treatment of patients with benign disease.
Abnormalities within the J H -C intron
Both immunophenotypic and molecular genetic studies indicate that most cases of CLL have not undergone CSR on either the expressed (functional) or non-functional IGH alleles. Only rare cases of CLL express Ig isotypes other than IgM. 66 The possible clinical significance of CSR and its relationship to V H mutations have not been directly explored. Given that CSR occurs in normal B cells after the onset of SHM, it is likely that CLL that express IgG and other isotypes will also harbor V H mutations.
However, in Southern blot studies a number of investigators have noticed a high frequency of abnormalities within the J H -C intron in CLL (Refs 67, 68 and MJSD, unpublished observations). These abnormalities fall into two separate categories. Firstly, using a C probe, no rearrangements should be detected by Southern blotting following digestion with a number of restriction enzymes including HindIII, PstI, SacI and BglII, due to the presence of restriction sites in the J H -C intron. With these enzymes, C should retain germline configuration in both normal and malignant cells. Secondly, with restriction enzymes that have no sites within the J H -C intron, such as BamHI, both J H and C should be on the same DNA fragment. The presence of an unexpected BamHI site may be detected by lack of comigration of the two fragments and may represent either IGH chromosomal translocations or Leukemia abnormalities of CSR. Interphase FISH studies using probes spanning the IGH locus indicate that the frequency of such translocations is genuinely low, and probably less than 2% of all cases of CLL. However, the frequency of CSR aberrations in CLL (which would not be detected by the assay) has not been determined. Laffan and Luzzatto 69 documented two cases of B cell prolymphocytic leukemia with an unexpected BamHI site with lack of comigration of C and J H , which were shown by bacteriophage cloning to represent an inversion within IGH, presumably arising as an error of CSR, resulting in a head-to-head juxtaposition of C and one of the downstream C␥ segments. 69 This kind of abnormality would appear to be relatively rare, occurring in 4/178 cases studied by Laffan and Luzzatto.
In contrast, local abnormalities may be seen in up to 30-40% of cases of CLL. Limited DNA sequencing of such rearrangements has shown that these changes represent both mutations as well as insertions, duplications and deletions throughout the J H -C intron, but specifically within the 5′ portion of the S region. An example of one case in which a point mutation introduced a novel BamHI site is shown in Figure 2 . From restriction map analysis, these changes appear to cluster to the region immediately 5′ to, and involving the 5′ region of the repetitive switch region upstream of C. However, a comprehensive sequence analysis of such alterations in a well-characterized series of CLL is lacking. Such changes are not specific to CLL, and are seen at lower frequency in other B cell malignancies and presumably reflect the action of the SHM mechanism outside the recombined VDJ gene. The relationship of these changes within the J H -C intron to V H mutations and their possible significance in terms of IGH gene expression remain to be determined. If these mutations extend into the enhancer within the J H -C intron, they may account in part for the low-level IGH expression seen in CLL.
Other mutational events in CLL BCL6 mutations:
A number of other mutational events have been observed in CLL. Firstly, mutations within the first intron of the BCL6 gene have been seen in between 23 and 42% of cases in three studies. [70] [71] [72] Comparable somatic mutations occur in normal B cells during their transition through the normal germinal center reaction and are thought to represent the action of the SHM outside the confines of the IG loci. 73 As with the changes in the J H -C intron, they consist of point mutations, which may be biallelic, deletions and insertions. They are clustered in the same region in which chromosomal translocation breakpoints occur in diffuse large B-NHL. Similar mutations have been found recently in a number of other genes, which like BCL6 also undergo chromosomal translocation in mature B cells. These data therefore suggest that genetic regions susceptible to such apparently SHM-mediated mutation may be targeted for translocation. 74 Chromosomal translocations involving BCL6 have not been reported in CLL, but mutations within the first intron are common. The relevance of these mutations in terms of BCL6 expression is not clear. CLL express only low levels of BCL6 protein. Moreover, the relationship of BCL6 mutations to V H mutations is controversial. One group, in a study of 34 cases reported a close relationship, with all eight cases with BCL6 mutations having V H mutations. 72 In contrast, another group found no clear parallel, suggesting the operation of separate mechanisms. 71 Further studies are required to resolve this apparent discrepancy.
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Figure 2
Mutations, deletions and duplications within the 5′ S region in B cell malignancies. Nucleotide sequence of Wien 133 clone B511 compared with that of normal fetal liver human IGH S (middle sequence, accession number X56794), and to a rearranged IGH allele cloned from a patient with ALL (bottom sequence, accession number X54713). Nucleotides in bold and marked with asterisks indicate B511 mutations compared with the normal sequence. Point mutation in B511 at nucleotide 388 created a BamHI site (highlighted). Underlined regions are duplicated sequences. B511 contained several small insertions, the largest of which, 67 bp (region I) was almost an exact duplication of the preceding 67 base pair (region P). Region P also contained several point mutations compared with the germline sequences. Some of these mutations were duplicated in region I. However, region I contained further deletions not seen in region P, suggesting that point mutational mechanisms operated both before and after duplication of the region. A second, smaller region (14 base pair) had also undergone a similar duplication and mutation process.
CD79b mutations:
The B cell antigen receptor (BCR) is a multimeric complex, in which sIg is non-covalently associated with two other proteins, CD79a and CD79b. These proteins are necessary for cell surface expression and for signal transduction.
75 CD79b is also necessary for the maintenance of allelic exclusion during normal B cell development. 76 In keeping with their lower level expression of sIg, CLL cells express either low or absent levels of CD79b mRNA. Sequence analysis of cDNA clones from cases of CLL with low-level expression of CD79b showed point mutations, insertions or deletions that were largely located in the CD79b transmembrane and cytoplasmic domains, the latter containing the ITAM motif necessary for signal transduction. 77 Functional analysis of some CD79b mutations in a Jurkat model showed impaired BCR signaling. 78 Together, these results suggest that acquired CD79b abnormalities may underlie the diminished surface BCR display and loss of BCR signaling characteristic of CLL. However, mutations of this gene have not been confirmed in other series of CLL and the presence of mutations in genomic DNA has not been demonstrated. 79 Instead, mRNA alternative splicing with deletion of the exon that encodes the extracellular Ig-like domain, has been proposed to account for diminished BCR signaling in CLL. 79 Moreover, the expression of more than one IGH isotype in CLL does not appear to be dependent on the presence of CD79b mutations. 80 Interestingly, the CD79b promoter is methylation sensitive, not only at the usual CpG methylation sites, but also at CC(A/T)GG sites. Methylation of the latter blocked the binding of early B cell factor (EBF), which is necessary for transcription. This may have implications for epigenetic control of gene expression.
81
IG chromosomal translocations in B-CLL
Whilst nearly all subtypes of B-NHL and the majority of cases of myeloma are associated with specific IG chromosomal translocations, it is clear from both metaphase cytogenetic analysis and from interphase FISH using probes spanning the IGH locus (ie split of differentially labeled V H and C␣ probes), that comparable rearrangements in CLL are rare. 1 Early studies suggesting that t(11;14)(q13.3;q32.3) involving IGH with the cyclin D1 locus was common in CLL, almost certainly included cases of mantle cell lymphoma in leukemic phase or splenic lymphoma with villous lymphocytes (SLVL). To our knowledge, this translocation has not been reported in bona fide CLL.
Why CLL should lack a common recurrent IG translocation is not clear. A comparable lack of IG translocations is seen in B cell precursor acute lymphoblastic leukemia (BCP-ALL). The lack of IG translocations in these two diseases may reflect the lack of activity of the intronic IGH enhancer. In B cell precursors the intronic enhancer does not appear to be active, 25 whilst in CLL the mutations, deletions and insertions within the J H -C intron may result in loss of activity. A confounding point in CLL is that some cases with translocations involving 14q32 do not in fact involve the IGH locus, but instead involve another, as yet unidentified, more centromeric locus within the band, all the IGH complex being translocated to the other derivative chromosome (unpublished observations). Whether these non-IGH 14q32 translocations involve BCL11B as has been documented recently in a subset of T cell precursor ALL cases with t(5;14)(q31;q32) remains to be determined.
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Nevertheless IG translocations do occur in B-CLL albeit at low frequency, probably less than 2% of all cases. Their spectrum and the mechanisms underlying their origins are probably different from those seen in other B cell malignancies. The pathological consequences of these translocations are deregulated expression of the incoming oncogene due to the physical juxataposition of the IG enhancers either within the J H -C intron or 3′ of C␣. In some instances in B-NHL it has been shown that translocation is associated with mutation and deletion of the translocated allele presumably due to the continuing action of SHM. Mutations within the amino terminus of BCL2, a domain that has cell-cycle regulatory functions, have for example been associated with transformation of lowgrade disease. 83, 84 However, due to their rarity, the possible link of IG translocations to V H mutational status has not been determined in most cases.
Although rare, IG translocations in CLL are of interest for the light they shed on the pathogenesis of CLL and other B cell malignancies.
BCL2 (18q21.3) translocations
BCL2 was isolated from its direct involvement in t(14;18)(q32.2;q21.3), which is seen in about 80% of cases of follicular B-NHL. In this disease, most of the translocation breakpoints involve the 3′ region of the gene, either within the 3′ untranslated region or in a number of other cluster regions more telomeric. [85] [86] [87] Analysis of both derivative chromosomes has indicated that the breaks may occur in a restricted period of B cell development within the germinal center. 88 These translocations result in deregulated BCL2 expression, which through its anti-apoptotic action is thought to promote survival of cells otherwise destined to die within the germinal center. This, with the accumulation of other mutations, particularly involving MYC on chromosome 8q24.1, which has marked synergistic activities with BCL2, allows the appearance of the full neoplastic phenotype in the context of B-NHL.
High-level BCL2 expression is seen in most cases of CLL and this may arise from changes in promoter methylation, rather than chromosomal translocations. 89 Nevertheless, some cases do exhibit translocations. Interestingly, unlike the follicular B-NHL that typically involve the IGH locus and specifically the J H segments, in CLL many of these translocations are 'variant'. These translocations are analogous to the 'variant' MYC translocations in Burkitt lymphoma as they involve the IG light chain genes on chromosomes 2p12 (IGK) or 22q12 (IGL). However, they additionally differ from typical BCL2 translocations in follicular B-NHL since they involve the 5′ end of the BCL2 gene. [90] [91] [92] [93] These breaks are therefore some 120 kb centromeric of those within the 3′ region of the gene.
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The distinct anatomy of BCL2 translocations in CLL suggests a mechanism distinct from that seen in follicular B-NHL. The DNA 5′ of the BCL2 gene is particularly CpG rich and it has been suggested that it may adopt a particular configuration, which may predispose to chromosomal translocation formation. 95 Interestingly, from the limited work that has been done, it may be that the region 5′ of BCL2 may also be subject to hypermutational changes. 96 Although translocations involving the 5′ region of BCL2 are seen predominantly in CLL, similar events are also observed in follicular B-NHL. Between 1-2% of cases of CLL exhibit BCL2 translocations. 93, 97 It would appear from sequential cytogenetic and molecular analyses, that BCL2 translocations can be a secondary event in some of these cases (DGO, unpublished observations).
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It is of interest that the mouse E-BCL2 transgenic model, which effectively recapitulates the t(14;18)(q32.3;q21.3) in all B cells, exhibits no increase in CD5 + B cells. Other B cells accumulate due to the loss of normal apoptotic mechanisms. This may reflect the endogenous high-level expression of BCL2 in CD5
+ cells, and raises the question as to whether the IG-BCL2 translocations involve other target genes in CLL. However, it should be noted that CD5
+ B cell populations in mouse and man may not be directly comparable. 98 There are two aspects to the BCL2 translocations in CLL that have not yet been adequately explored. Firstly, there is another gene (FVT1) immediately telomeric of BCL2, which may also be deregulated as a consequence of some 5′ BCL2 translocations. 99 The possible contribution of this gene to the pathogenesis of CLL with 5′ BCL2 translocations remains to be explored. Secondly, the anatomy of the rare IGH-5′ BCL2 translocations has not yet been determined completely (Figure 3) . The 3′ BCL2-IGH translocations do not pose any anatomical problems, but the involvement of the 5′ end of the same gene with the same region of IGH demands a chromosomal inversion or insertion of DNA from one chromosome to another. The origins of the telomeric DNA on either derivative chromosome would shed some light on this process. Like the 13q14 deletions, these translocations in CLL are likely to be complex events and not simple 'cut and paste' events and imply a distinct pathogenic mechanism.
BCL3 (19q13.3) translocations
Like BCL2, this gene was isolated through its direct involvement in t(14;19)(q32.3;q13.3) observed in two cases of CLL. 100 Initially, this translocation was thought to be common, but subsequent cytogenetic and molecular (principally Southern blot) analysis has shown this is not the case. The frequency of the translocation has been estimated to be about 0.1% of cases of CLL. 101, 102 Most but not all cases with this translocation are CLL and most of these exhibit trisomy 12 in addition to the t(14;19)(q32.3;q13.3). Many of the cases have been seen in younger patients with rapidly progressive and/or transformed disease.
The structure of the translocation is of some interest as most cases involve one of the S␣ regions. Only one case has been reported involving S. These data would suggest that the translocation occurs as an error in CSR. However, CSR in CLL and specifically CSR to S␣ of the productive alleles, is rare in CLL and these data would therefore suggest a specific pathogenic mechanism. Breakpoints in BCL3 occurred in two cluster regions immediately upstream (centromeric) of the BCL3 promoter and about 15 kb further upstream. In both, the consequences of translocation were deregulated expression of full-length BCL3, since in all instances the BCL3 open-reading frame was not directly affected. Other breakpoints fell outside either cluster region. The V H mutational status of CLL with t(14;19)(q32.3;q13.1) is not known.
The functions of BCL3 are of some interest, since like several other genes such as REL and BCL10 involved in the pathogenesis of B cell malignancy, it regulates NF-B activation. BCL3 is a member of the IB family of proteins that regulate the NF-B family of transcription factors. 103 Unlike other IB family members, BCL3 is a nuclear protein and contains amino-and carboxy-terminal transactivation domains. BCL3 associates with homodimers of p50 or p52 NF-B subunits. These have no defined transactivation domains and, as homodimers, may competitively inhibit the binding of transactivat-
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Figure 3
Schema depicting BCL2 chromosomal translocations in follicular B-NHL and CLL. The BCL2 gene is located on chromosome 18q21.3 and is transcribed from telomere to centromere (top panel, red boxes). There are four common recurrent breakpoints within BCL2, three falling within the 3′ region of the gene, centromeric to the coding regions and a loose cluster immediately 5′ of the gene within a large CpG island. FVT1 (http://www.ncbi.nlm.nih.gov/LocusLink/LocRpt.cgi?l=2531) is composed of nine exons and is located immediately telomeric of BCL2 and is transcribed in the opposite orientation (green boxes). In follicular lymphomas, the IGH breaks occur almost exclusively within the J H segments and become fused to one of the 3′ breaks within BCL2. This is shown in the middle panel. In contrast in CLL, the 5′ end of the BCL2 is often involved (bottom panel). This implies that some form of chromosomal inversion has to occur in addition to the translocation. The complete nature of such translocations has not been determined. ?? denotes that the origin of the telomere in the derivative chromosomes is not known. In follicular B-NHL, the IGH locus has nearly always undergone CSR (but see Ref. 117 for an interesting novel break in S), whereas the configuration in CLL is not known.
ing NF-B dimers to consensus DNA binding (B) sites. BCL3 can therefore act as an anti-repressor to remove homodimers from B sites, so that transactivating NF-B dimers can bind or act as a transactivator by forming complexes with homodimers at B sites or enhance homodimer binding to B sites. However, BCL3 also interacts with several other proteins, suggesting that the protein may have other effects outside its NF-B regulatory functions. Functionally, BCL3 expression was able to suppress apoptosis induced by withdrawal of IL4. 104 BCL3 has recently been shown to stimulate cyclin D1 expression via activation with NF-B p52 homodimers. 105 E -Bcl3 transgenic mice which should recapitulate CLL with high-level BCL3 expression due to t(14;19)(q32.3;q13.1), were characterized by an accumulation of mature B cells in bone marrow, lymph nodes and peritoneal cavity. 106 They demonstrated a hyper-responsive humoral immunity as evidenced by an increased sensitivity to BCR cross-linking, increased levels of autoantibody to double-stranded DNA, and a three-fold increase in the number of germinal center cells in lymph nodes. However, no lymphoid neoplasms were seen in transgenic animals. These data indicate that like BCL2, additional genetic events over and above the deregulated expression of BCL3 are required for the full neoplastic phenotype to emerge.
BCL11A (2p13) translocations
Again, this gene was isolated through its direct involvement in another rare chromosomal translocation, t(2;14)(p13;q32.3) in three cases of CLL and one case of immunocytoma that progressed to leukemic phase. 15 Two of the three cases of CLL occurred in young children aged 10 and 15 years. This is a rare, if not unique, diagnosis. 107 In two, t(2;14)(p13;q32) was the sole cytogenetic abnormality, indicating that this gene may be of primary importance in the pathogenesis of the disease. Similarly, the murine homolog (Evi9) was isolated through its ability to induce acute myeloid leukemia in an insertional retroviral mutagenesis model. 108, 109 Although the human gene is expressed in early, multipotent hemopoietic progenitors, the contribution of this gene to the pathogenesis of myeloid leukemias has yet to be assessed. 110 BCL11A maps closely telomeric to REL on chromosome 2p13 and is coamplified with REL in most cases of amplifications of this region that occur commonly in Hodgkin's disease and in mediastinal and other B cell non-Hodgkin's lymphomas, although the contribution of BCL11A to these malignancies is not yet clear. 15, 111 Like the BCL3 translocations, BCL11A translocations involve switch regions but in this instance in both cases analyzed, it was S␥2 that was involved. All three cloned breaks fell within 175 base pairs of each other immediately upstream (centromeric) of a large CpG island associated with the 5′ end of BCL11A. Like BCL3 translocations therefore, the result on the derivative chromosome 14 was a head-to-head arrangement with IGH and BCL11A in opposite transcriptional orientations. The consequence of the translocation was deregulated expression of BCL11A. This gene exists in three common RNA isoforms. All three were co-ordinately over-expressed in cases with the translocation. Interestingly, all cases with t(2;14)(p13;q32) exhibited germline unmutated V H genes. 112 Although this translocation is clearly rare, the BCL11A gene is of interest since like BCL6, it encodes a highly conserved, germinal-center specific, Krü ppel zinc finger transcriptional repressor protein. BCL6 and BCL11A interact directly indicating that they may function to control the same subset of genes in mature B cells. Whether BCL11A fulfils the functions of BCL6 in CLL, where expression of the latter gene is relatively low, is not known. The closely related BCL11B gene is 981 SPOTLIGHT expressed predominantly in T cells, implying tight lineage transcriptional control of expression of these two genes. 15, 82 Whether BCL11A undergoes mutation in the same manner as BCL6 in both normal and malignant B cells is also not known.
CCND2 (12p13) translocations
One case of Richter's transformation of CLL has been reported with a t(12;22)(p13;q12) translocation involving the IGL light chain with the promoter of the cyclin D2 (CCND2) gene. 113 Again, although this translocation appears to be rare, if not unique in CLL, the biology of the consequence is of considerable interest. Apart from its role in regulating the cell cycle, cyclin D2 has other specific roles in B cell development and signaling via the BCR. 114 Mice in which the cyclin D2 gene has been inactivated specifically lack B cells of the CD5 + lineage indicating an essential role for this gene in murine CD5 + B cell development. Moreover, cyclin D2-deficient mice fail to proliferate in response to signals mediated via the BCR, although signaling via CD40 remains intact. These and recent functional data, indicate a role for cyclin D2 in antigendependent B cell clonal expansion via the Rho-family guanine-nucleotide exchange factor, Vav. 115 The possible role of disruption of this pathway in other cases of CLL lacking translocations of the CCND2 gene has not been investigated.
It is of interest that all three human cyclin D genes are involved in IG translocations in varying stages of malignant B cell development. Whether the other cyclin D proteins also signal via the same pathway in malignant B cells is not clear.
Concluding remarks
Although abnormalities of the IG genes are not directly implicated in the pathogenesis of CLL in the same way as they are in the B-NHL, study of the configuration of these genes has allowed fundamental insights into the pathogenesis of these diseases and has allowed the development of new and powerful prognostic markers. Whether these genes and proteins can be used to develop novel tumor-specific therapies remains an interesting prospect. The possibility that some 'superantigens' are implicated in the pathogenesis of some subsets of CLL is fascinating. Through the use of high-throughput screening methods, it should become possible to identify the antigens involved, and perhaps design small molecules that interact specifically and induce apoptosis via the tumor-associated immunoglobulin either directly or via the associated signaling pathway. 116 
